Generic drug of the therapeutic class: Rheumatology
Active ingredients: Dantrolene
laboratory: Merck Sante
Lyophilisate for IV injection
Box of 1 vial of 20 mg
Treatment of perianesthetic malignant hyperthermia, in combination with general management measures.
Dosage INTRAVENOUS DANTRIUM 20 mg Lyophilisate for IV injection Box of 1 vial of 20 mg
In relation to weight, the doses in adults and children are identical.
Treatment of the crisis
As soon as the diagnosis of malignant hyperthermia is made, an initial dose of 2.5 mg / kg should be administered intravenously. Depending on the clinical response, additional doses of 1 mg / kg will be administered (every 5 to 10 minutes) until the symptoms subside (stiffness, hypercapnia, cardiac arrhythmias and hyperthermia).
During the first 24 hours, the total dose administered is usually of the order of 5 mg / kg, but in some cases cumulative total doses greater than or equal to 10 mg / kg have been required.
Prevention and management of the upsurge of the crisis
To prevent a recrudescence of the crisis, dantrolene will be continued at a dose of 1 to 2 mg / kg intravenously every 4 to 6 hours for 24 to 48 hours. (If the crisis was quickly resolved, it is possible to do an oral relay at a dose of 4 mg / kg / day in 2 or 3 doses for 48 hours.)
Each vial should be prepared by the addition of 60 ml of sterile water for injection, and shaken by inversion until a clear solution is obtained.
In an emergency situation, the solution can be filtered with a blood filter to eliminate the risk of crystal administration.
There is no known contraindication to the treatment of the malignant hyperthermia crisis.
Adverse effects Dantrium Intravenous
Dantrolene can induce:
· Muscular fatigue that may compromise the protection of the aerodigestive junction and ventilation,
· Uterine hypotonia,
· Rarely, an allergic skin reaction.
The manifestations of hepatotoxicity observed with the use of oral dantrolene have not been reported for short-term treatment of malignant hyperthermia.